Novo Holdings has completed its $16.5 billion acquisition of Catalent, the contract drug manufacturer said on Wednesday, days ...

Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the ...

Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment ...

Novo Holdings A/S said Monday that it has completed its $16.5 billion all-cash acquisition of Catalent ( CTLT, Financials ).

Indications are that Novo will be investing in both the plant and the community,” an Indiana University professor said.

Indications are that Novo will be investing in both the plant and the community,” an Indiana University professor said.

(RTTNews) - Wednesday, Novo Holdings A/S completed the acquisition of Catalent, Inc. (CTLT), a global contract development and manufacturing organization, in an all-cash transaction worth enterprise ...

A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end to the obesity ...

Nigeria will auction undeveloped oil and gas blocks next year, prioritising natural gas development to support the country's ...

Indeed, there weren’t many more biotech IPOs in 2024 than in 2023, and the companies that did venture out this year struggled ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk’s dominance in the weight-loss market.